Potential AD treatment candidates, such as DNMTs, Sirtuin 1 (SIRT1), and methyl-CpG-binding protein 2 (MeCP2), have been proposed following the exploration of a dynamic network that coordinates DNAm and histone modifications [234]. Here, MECP2 is linked to Alzheimer disease.